GlassScriptPhysician profile
Krishna K Pachipala
NPI 1386609188
$22,068.82
in general payments reported to CMS, 2019-2025
61 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $6,954 · 2021: $7,171 · 2022: $1,863 · 2023: $1,992 · 2024: $573 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,961.14 |
| Education | $219.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,167.76 | 2019-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $3,176.98 | 2019-2025 | |
| Array Biopharma INC | $2,490.68 | 2021-2023 | Mektovi, Braftovi, Lorbrena |
| Astrazeneca Pharmaceuticals LP | $2,305.22 | 2019-2025 | Imfinzi |
| G1 Therapeutics, INC. | $1,538.93 | 2021-2022 | |
| R-Pharm US LLC | $1,352.86 | 2019 | |
| Amgen INC. | $654.75 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| Pfizer INC. | $601.04 | 2019-2025 | |
| Seagen INC. | $481.47 | 2020-2023 | Padcev |
| Janssen Biotech, INC. | $472.85 | 2019-2025 | Akeega, Erleada, Darzalex |
| Astellas Pharma US INC | $456.30 | 2019-2025 | Xtandi, Xospata |
| E.R. Squibb & Sons, L.L.C. | $418.15 | 2019-2024 | Opdivo |
| Glaxosmithkline, LLC. | $405.13 | 2020-2025 | Zejula, Jemperli |
| Gilead Sciences, INC. | $237.92 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $235.37 | 2019-2025 | Keytruda, Welireg |
Show all 59 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Pachipala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.